Patients with advanced melanoma enrolled onto our phase II clinical studies have been treated with autologous DC loaded with autologous tumor lysate/homogenate matured with a cytokine cocktail , showing a clinical benefit ( PR+SD ) in 55.5 % of evaluable cases to date .